Predictably, this has led to a flood of new patent applications. Microsoft held about 600 patents the day State Street was decided. Today it holds nearly 9,000 patents. Amazon's much-derided one-click patent was approved the year after the decision. Patent litigation in the software industry has exploded with firms facing lawsuits over patents covering extremely broad software concepts such as wireless e-mail, web embedding, and converting IP addresses to phone numbers. Technically, these patents cover general purpose computers executing the algorithms described in the patent rather than the algorithms themselves. But because no one executes such algorithms with pen and paper, the net result has been to give the patent holders effective monopolies on the algorithms themselves.
[...]
Several parties submitted briefs urging the Federal Circuit to reject software patents outright, but none of them were invited to participate in the oral arguments.
The death of the Patent Reform Act in the Senate spells hard times for open source.
That’s because one of the act’s main aims was to end “forum shopping,” the practice of filing lawsuits in, say, the Eastern District of Texas, which never saw a patent plaintiff it didn’t like.
The act would have also streamlined reviews of patent claims and made some other important reforms. It wasn’t perfect, but it was better than nothing.
[...]
To me, the most effective form of patent reform was not on the table. That is, eliminate software patentability entirely. Copyright provides plenty of protection, and what you’re patenting, in the end, is math.
Unlike Tim Lee, I haven't read Ben Clemens' book Math You Can't Use. Indeed, I just now heard of it for the first time. But good title! And it's a good subject for a book -- the case against software patents.
Cephalon spent $512,000 on lobbying in first quarter
[...]
The Frazer, Pa.-based company lobbied Congress on a bill aimed at updating the U.S. patent system. Software and computer companies supported the bill that passed the House last year, saying it would cut down on frivolous patent-infringement lawsuits. But the pharmaceutical industry argued it would weaken patent protections on drugs by reducing infringement penalties. The bill has stalled in the Senate.
--Richard Stallman